Revitalizing Pharma Collaborations: The Reblozyl Case Study
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the […]
Insights
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine
What Works, What Kills What, and Why It Matters By Mike Rea In pharmaceutical R&D, where billions ride on the
Minimizing Bias in Market Research: An Interview with Erik Coats
Minimizing Bias in Market Research: An Interview with Erik Coats By The Fulcrum Research Division Erik Coats is one of
2025 Collaborating for Novel Solutions (CNS) Summit: Annual Pharma Digital Innovation Index, cements leaders in the Biopharmaceutical innovation of digital solutions.
Tuesday, November 4th, 2025, Boston, MA – Today, the annual Pharmaceutical Digital Innovation Index, a partnership between IDEA Pharma, a
Challenges and Concerns Raised by EFPIA on Joint Clinical Assessments
In the healthcare regulation sphere, proposed EU-level joint clinical assessments (JCAs) have sparked debate in the pharmaceutical industry. A recent EFPIA report highlights concerns about the rigidity of the guidelines, particularly in oncology, and suggests revisions to ensure a more efficient and adaptable evaluation process that accommodates diverse stakeholder needs across Europe.
Joint Clinical Assessment (EU HTA) Explained
A Comprehensive Exploration of Competitive Intelligence, Knowledge-Sharing, and Strategic Optimization in the Evolving Landscape of EU Health Technology Assessments. The